Home / News / Press Releases
News & Updates— Press Releases

News & Updates Press Releases

Veos Pharmaceuticals Launches ThymoTropin™ to Support Muscle Health and Preservation on Weight Loss and Aging Journeys

Back to all press releases
Product Launch January 16, 2025 · 1:31 PM GMT+1 Madrid, Spain

Veos Pharmaceuticals Launches ThymoTropin™ to Support Muscle Health and Preservation on Weight Loss and Aging Journeys

Clinically Proven Myostatin-Targeting Formula to Enhance Muscle Growth, Repair, and Endurance.

MADRID, SPAIN / ACCESS Newswire / January 16, 2025 / Veos Pharmaceuticals, a leading innovator with a portfolio of nearly 40 products spanning the EU, US, and Canada, today announced the launch of ThymoTropin™, a revolutionary over-the-counter (OTC) solution for muscle growth, repair, and preservation. ThymoTropin™, powered by clinically validated thymol and carvacrol, represents a first-of-its-kind product targeting myostatin regulation, a critical mechanism for maintaining muscle mass and performance.

As part of Veos Pharma's commitment to delivering science-backed innovations, ThymoTropin™ addresses the unique needs of individuals experiencing muscle loss due to aging, chronic disease, or weight management regimens, including GLP-1 treatments and calorie-restricted diets.

Filling a Critical Gap in Muscle Health

More than 50% of individuals undergoing weight loss or battling chronic illnesses face muscle loss, impacting their mobility, strength, and overall health. ThymoTropin™ is formulated to counteract this decline by preserving and enhancing muscle mass through its innovative dual-action mechanism:

"At Veos Pharmaceuticals, we are committed to addressing critical health gaps with effective, science-driven solutions. ThymoTropin™ is a game-changer in muscle health, offering proven benefits for individuals managing muscle loss while aligning with modern health goals, including weight loss and aging-related care." — Dr. Bassam Damaj, Executive Chairman of Veos Pharma

Clinically Backed, Patented Innovation

ThymoTropin™ is supported by a robust patent portfolio, including:

Patent Portfolio

  • CA Patent No. 2,964,239 — Applications of Monoterpenes in Muscle Health
  • EP Patent No. 3191086 — Monoterpene Formulations for Muscle Enhancement
  • PT Patent No. 3191086 — Monoterpenes for Myostatin Regulation

Clinical results demonstrate up to a 50% increase in muscle mass and 37% improvement in endurance. ThymoTropin™'s unique focus on myostatin regulation differentiates it from traditional protein supplements, making it a superior solution for muscle health.

+50%
Muscle mass
increase
+37%
Endurance
improvement
3
Patents
granted

Targeted Nutrition for Growing Market Needs

The global market for muscle health and repair products continues to grow, driven by increasing demand from aging populations, oncology patients, and fitness-conscious individuals. ThymoTropin™ directly addresses these needs by providing:

In a competitive landscape dominated by protein supplements like Abbott's Protality™ and Nestle Boost, ThymoTropin™ stands out with its clinically validated myostatin regulation mechanism. Unlike traditional products, ThymoTropin™ offers targeted efficacy without unnecessary calories or sugars, making it an ideal solution for modern health-conscious consumers.

Growing Market Opportunity and Competitive Landscape

The global muscle health and nutritional support market is projected to exceed $15 billion by 2025, driven by increasing demand from aging populations, oncology supportive care, and weight management solutions.

Competitor products such as Abbott's Protality™ and Nestle Boost™ have collectively generated impressive sales:

ProductAnnual RevenueMarket Share
Protality™ (Abbott)~$300 million15%
Boost® (Nestlé)~$500 million25%
Traditional whey protein supplements> $8 billion60%

While competitor products focus on general protein supplementation, ThymoTropin™ sets itself apart by targeting myostatin regulation, offering a precise and effective solution for muscle growth and preservation without unnecessary calories or sugars.

Available as an Ingredient for B2B Applications

ThymoTropin™ is offered as a premium ingredient for business-to-business (B2B) formulations. This enables manufacturers in the health, nutrition, and functional food sectors to incorporate ThymoTropin™'s proven myostatin-targeting benefits into their products, meeting growing consumer demand for advanced muscle health solutions. Veos Pharma partners with businesses to provide customized solutions and ensure seamless integration into existing product lines.

About Veos Pharmaceuticals

Headquartered in Madrid, Spain, Veos Pharmaceuticals S.L. is a global biotechnology company with a portfolio of nearly 40 products across the EU, US, and Canada. The company specializes in OTC solutions, biostimulants, and advanced nutritional products aimed at improving quality of life.

Veos Pharma's flagship products include Ocufresh®, BioPropello™, OliQuell™, OleoSorb™, VEOX-Preserve™, and ThymoTropin™.

For more information, visit www.veospharma.com.

Protality™ is a trademark of Abbott Laboratories. Boost® is a trademark of Nestlé.

References

Grand View Research — Sports Supplement Market Analysis

Nestlé, S.A. (SWX: NESN) public disclosures.
Abbott Laboratories (NYSE: ABT) public disclosures.

SOURCE: Veos Pharmaceuticals, SL

Share: in 𝕏 @

Media & Investor Contact

Veos Pharmaceuticals, S.L.
Calle Núñez de Balboa, 35 A-5 Planta Oficina A1
28001 Madrid, Spain
Email: info@veospharma.com
Telephone: +34 911 925 649
Website: www.veospharma.com

Forward-Looking Statements. This announcement may include forward-looking statements based on current expectations and involving risks and uncertainties. Actual results may differ materially. Veos Pharmaceuticals assumes no obligation to update or revise these statements after the date of publication.